摘要
目的 探讨环形电外科切除术(loop electrosurgical excision procedure,LEEP)在宫颈上皮内瘤变(CIN)伴高危型人乳头瘤病毒(HPV)感染患者中的应用效果.方法 采用LEEP治疗98例CIN伴HR-HPV感染患者,手术前后均行HR-HPV检测,观察手术效果及HR-HPV变化.结果 所有患者均顺利完成手术,术后随访1年,治愈率为90.8%(89/98),复发率为9.2%(9/98);其中CINⅠ患者治愈率为100%(64/64),显著高于CINⅡ~Ⅲ患者的73.5%(25/34)(P<0.01),CINⅠ患者复发率显著低于CINⅡ~Ⅲ患者(P<0.01).术后6个月HR-HPV阳性率为31.6%(31/98),显著低于治疗前(P<0.01),转阴率为68.4%(67/98);术后1年HR-HPV阳性率再次显著下降为15.3%(15/98)(P<0.01),转阴率为84.7%(83/98)(P<0.01).结论 LEEP治疗CIN疗效显著,且可消除大部分HR-HPV感染,降低CIN复发率及宫颈癌发生率,操作简便,并发症较少,值得推广.
Objective To study the clinical effects of loop electrosurgical excision procedure (LEEP) in cervical intraepithelial neoplasia (CIN) patients with high-risk human papilloma virus (HR-HPV) infection. Methods Ninety-eight CIN patients with HR-HPV infection were treated with LEEP. All patients were performed with HR-HPV test both before and after LEEP. Clinical effects of the patients were assessed. Results All patients were successfully operated. The cure rate was 90.8% (89/98), and the recurrence rate was 9.2% (9/98) after 1-year follow-up. The cure rate in patients with CIN Ⅰ was 100% (64/64), significantly higher than 73.5% (25/34) in patients with CINⅡ-Ⅲ(P<0.01), and the recurrence rate of patients with CIN Ⅰ was significantly lower than that of patients with CINⅡ-Ⅲ(0% versus 26.5%,P<0.01). Positive rate of HR-HPV was 31.6% (31/98) 6 months after the treatment, significantly lower than that before LEEP(P<0.01), and negative conversion rate was 68.4% (67/98);and 1 year later, they continued to decrease to 15.3% (15/98) and 84.7% (83/98), respectively, all with statistical significance (P<0.01). Conclusion LEEP is effective in the treatment of CIN, also it can eliminate most of the HR-HPV infections, thus reduce the recurrence rate of CIN and incidence of cervical cancer. In addition, it′s easy to operate, with fewer complications, and worthy of promotion.
出处
《微创医学》
2014年第1期61-63,共3页
Journal of Minimally Invasive Medicine
关键词
环形电外科切除术
宫颈上皮内瘤变
高危型人乳头瘤病毒感染
Loop electrosurgical excision procedure
Cervical intraepithelial neoplasia
High-risk human papilloma virus infection